26 evolution "https:" "https:" "https:" "Japan Agency for Marine Earth Science and Technology" Fellowship positions at City of Hope
Sort by
Refine Your Search
-
Dr. Zhaohui Gu’s lab, please visit: https://gu-lab.net and https://www.cityofhope.org/Zhaohui-Gu As a successful candidate, you will: Conduct independent and collaborative research in leukemia
-
: https://www.nathlab.org As a successful candidate, you will: Collaborate closely with experimental scientists, mathematicians, and medical oncologists/surgeons to plan, design, and execute computational
-
and progenitor cells and the bone marrow microenvironment, which provides essential context for understanding leukemia initiation, clonal evolution, and therapy response. For more information about Dr
-
, shaping the future of medicine through cutting-edge research. A Postdoctoral Fellowship position is available in the RSP Lab led by Dr. Sklavenitis Pistofidis. The RSP Lab (https://rsplab.org ) leverages
-
models to study metabolic diseases is preferred. For a complete list of Publications please visit here: https://www.ncbi.nlm.nih.gov/myncbi/1J54E41I5YVku/bibliography/public/ Your qualifications should
-
Fellowship position is available in the RSP Lab led by Dr. Sklavenitis Pistofidis. The RSP Lab (https://rsplab.org ) leverages advanced multi-omic technologies, coupled with experimental perturbations and
-
approaches developed in the lab, and develop novel cancer immunotherapies targeting metastatic cancer cells. Cancer immunotherapy is one of the most important breakthroughs in the development of cancer
-
, Cancer Biology, Chromatin Regulation, Cancer Epigenetics, Epigenetics Regulation, Cancer Metabolism, Immunology, Drug Discovery, Development, and Structural Biology, with an emphasis on RNA epigenetics
-
the Department of Hematological Malignancies Translational Science, Department of Pediatrics, and Gehr Family Center for Leukemia Research. You will directly work on the following projects: 1) Development
-
: · Contribute to the development of CD38 antibody‑drug conjugates (ADCs) and other multiple myeloma targets, including monoclonal antibody (mAb) engineering, ADC conjugation, biophysical characterization (SPR